Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study
German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...
CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...
Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025
China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...
Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China
Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...
R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech
Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...
Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...
Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...
CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...
Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations
Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...
Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...
Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy
The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...
Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...
NMPA’s New Guidelines for Drug Registration Review
A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...
Shanghai’s Three-Year Plan to Boost Elderly Care Quality
A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...
NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer
The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...
Tianjin Municipality Boosts Biopharmaceutical Industry with New Measures
An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:The...
Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...
NMPA Seeks Public Feedback on Export Drug Manufacturing Rules
An In – Depth Look at the New Draft Proposal for the Administration and Management...
VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally
China-based gene delivery technology developer VectorBuilder has formed a strategic alliance with compatriot firm Shenzhen...
China’s Drug Procurement Under Scrutiny: Addressing Quality Concerns and Policy Reforms
An In – Depth Exploration of the Recent Survey on Bulk Drug Procurement in China...